UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):	 	October 8, 2010	

HALOZYME THERAPEUTICS, INC. 
__________________________________________
(Exact name of registrant as specified in its charter)

Delaware	001-32335	88-0488686	
_____________________
(State or other jurisdiction	_____________
(Commission	______________
(I.R.S. Employer	
of incorporation)	File Number)	Identification No.)	
  	 	 	
11388 Sorrento Valley Road, San Diego, California	 	92121	
_________________________________
(Address of principal executive offices)	 	___________
(Zip Code)	
 	 	 	
Registrant’s telephone number, including area code:	 	858-794-8889	
Not Applicable
______________________________________________
Former name or former address, if changed since last report
  
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
In connection with the reorganization of Halozyme, Inc. (the operating subsidiary of Halozyme Therapeutics, Inc.) announced on October 11, 2010, Dr. Jonathan Leff is no longer serving as Halozyme’s Vice President and Chief Medical Officer. Dr. Leff’s last day of employment at Halozyme will be October 15, 2010. Halozyme appreciates the efforts and contributions of Dr. Leff during his time with Halozyme.

Top of the Form
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 	 	HALOZYME THERAPEUTICS, INC.	
  	 	 	 	 	
October 14, 2010	 	By:	 	James E. Cartoni	
 	 	 	 		
 	 	 	 	Name: James E. Cartoni	
 	 	 	 	Title: Secretary and Vice President, Legal